Drug intelligence / Profile preview

cereclatulin

Development stage: Unknown
Lead developer: Shenzhen Mingsairuilin Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Cereclatulin (MSL-101, Xilieketuoling) is a recombinant humanized monoclonal antibody targeting CD24 (Cluster of Differentiation 24), developed by Shenzhen Mingsairuilin Pharmaceutical. CD24 is a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that plays a pivotal role in regulating the innate immune response and inflammatory signaling, often through its interaction with Siglec-10. By targeting CD24, cereclatulin aims to suppress pathological inflammation and restore immune homeostasis in conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Additionally, it is being investigated for diabetic retinopathy, where it may address vascular inflammation and leakage by modulating CD24-mediated pathways. The drug is currently in Phase II clinical development for SLE and diabetic retinopathy, administered via intravenous infusion.

Brand names: Xilieketuoling
Other names: 希列克妥灵

Targets

CD24 (Cluster of Differentiation 24)

Beyond the preview

Go deeper on cereclatulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cereclatulin.

Explore the full profile